| 44.96 0.69 (1.56%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 53.21 | 1-year : | 62.15 |
| Resists | First : | 45.55 | Second : | 53.21 |
| Pivot price | 43.28 |
|||
| Supports | First : | 42.44 |
Second : | 40.52 |
| MAs | MA(5) : | 44.56 |
MA(20) : | 42.79 |
| MA(100) : | 43.2 |
MA(250) : | 41.42 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 85.6 |
D(3) : | 87  |
| RSI | RSI(14): 61.8 |
|||
| 52-week | High : | 49.61 | Low : | 33.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EXEL ] has closed below upper band by 16.6%. Bollinger Bands are 10.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.05 - 45.23 | 45.23 - 45.38 |
| Low: | 43.26 - 43.48 | 43.48 - 43.67 |
| Close: | 44.58 - 44.94 | 44.94 - 45.25 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Wed, 08 Apr 2026
Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)? - Sahm
Sat, 28 Mar 2026
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 - Yahoo Finance
Thu, 26 Mar 2026
Vanguard disaggregates holdings; Exelixis (NASDAQ: EXEL) shows 0 shares - Stock Titan
Tue, 03 Mar 2026
EXEL Financials: Income Statement, Balance Sheet & Cash Flow | Exelixis Inc - Stock Titan
Tue, 10 Feb 2026
EXELIXIS, INC. SEC 10-K Report - TradingView — Track All Markets
Tue, 10 Feb 2026
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 260 (M) |
| Shares Float | 211 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 103 (%) |
| Shares Short | 26,350 (K) |
| Shares Short P.Month | 28,810 (K) |
| EPS | 2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.22 |
| Profit Margin | 33.7 % |
| Operating Margin | 39.4 % |
| Return on Assets (ttm) | 19.2 % |
| Return on Equity (ttm) | 35.5 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 8.62 |
| Sales Per Share | 8.93 |
| EBITDA (p.s.) | 3.54 |
| Qtrly Earnings Growth | 84.1 % |
| Operating Cash Flow | 884 (M) |
| Levered Free Cash Flow | 631 (M) |
| PE Ratio | 16.17 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 5.03 |
| Price to Cash Flow | 13.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|